My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
July/August 2016
FROM THE PRESIDENT
IDSA Advocacy on ID-Led Stewardship—More Progress on our Strategic Priorities
IDSA and the Society for Healthcare Epidemiology of America (SHEA) are urging the Centers for Medicare and Medicaid Services (CMS) to establish antimicrobial stewardship programs (ASPs) as a condition of participation in Medicare and Medicaid, and in so doing, making our case for why these programs should be led by infectious diseases physicians. ID physician leadership of ASPs is a top priority of the Society and we are encouraged by this progress by CMS given our advocacy efforts.
TOP STORIES
Don’t Miss These IDSA Guidelines Updates
IDSA's Standards and Practice Guidelines Committee has been hard at work finalizing several guidelines that are critical to the work of our members. Look to the Patient Care and Science section of this issue of IDSA News to find updates on the following guidelines:
  • Coccidioidomycosis (Valley Fever)
  • Drug-Susceptible Tuberculosis
  • Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia
  • Hepatitis C Virus Infection
IDSA Honors 111 Distinguished Physicians, Scientists with FIDSA
Join IDSA in congratulating the outstanding physicians and scientists who have been awarded Fellow status by the Society. Each of these 111 individuals have achieved professional excellence and provided significant service to the field of ID and are leaders in their institutions and communities. FIDSA status is awarded annually by the IDSA board of directors.
IDWeek 2016: Not-to-Miss Sessions Featuring the Latest on the Zika Outbreak
Three exciting sessions at IDWeek 2016 will provide lessons on diagnosing, treating, and managing the Zika outbreak by those on the front-lines. Don’t miss the Opening Plenary featuring Mauro Schecter, MD, PhD, with the Projeto Praça Onze in Rio de Janeiro, Brazil.
Journal Club
Isavuconazole as Another Option for Treatment of Mucormycosis; Neurologic Signs and Symptoms Common in Acute HIV Infection; Prevention of Mother-to-Child Hepatitis B Transmission with Tenofovir
Upcoming dates to remember


The combined meeting of IDSA, SHEA, HIVMA, and PIDS, Oct. 26-30, 2016, in New Orleans. See you there!

PATIENT CARE AND SCIENCE
Updated IDSA Guideline on Valley Fever Published in CID
Drug-Susceptible Tuberculosis Guidelines Now Available
Updated Guideline on Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia Now Available
HCV Guidance Website Updated to Reflect Latest Drug Developments
IDSA Partners with AGA on New Registry to Track Fecal Microbiota Transplants
CLSI Updates on Antimicrobial Susceptibility Testing Are Now Available
CDC Issues Travel Warning for Area in Miami Due to Locally Transmitted Zika Virus; Generic Version of Tamiflu Approved by FDA
CLINICAL PRACTICE MANAGEMENT
Virtual Supervision of “Incident To” Services
POLICY AND ADVOCACY
Take 3 Minutes to Tell the UN to Take Global Action on Antimicrobial Resistance
As US Cases Mount, IDSA Continues To Push for Zika Funding
Massachusetts Passes Troubling Lyme Legislation
Party Platforms Include IDSA Priorities
GLOBAL HEALTH
Live from Durban: Science Speaks Covers AIDS 2016
EDUCATION AND RESOURCES
Stipends Available to ID Medical Student Interest Groups
Vaccines Virtual Collection from CID
Upcoming Webinar on Antibiotic Drug Development
YOU AND YOUR COLLEAGUES
IDSA, HIVMA Seek Clinical Practice Guidelines Editor
FROM THE PRESIDENT
IDSA Advocacy on ID-Led Stewardship—More Progress on our Strategic Priorities
TOP STORIES
Don’t Miss These IDSA Guidelines Updates
IDSA Honors 111 Distinguished Physicians, Scientists with FIDSA
IDWeek 2016: Not-to-Miss Sessions Featuring the Latest on the Zika Outbreak
Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.

Unsubscribe here